Skip to main content
Journal cover image

Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.

Publication ,  Journal Article
Feng, Y-X; Wang, T; Deng, Y-Z; Yang, P; Li, J-J; Guan, D-X; Yao, F; Zhu, Y-Q; Qin, Y; Wang, H; Li, N; Wu, M-C; Wang, H-Y; Wang, X-F; Xie, D ...
Published in: Hepatology
February 2011

UNLABELLED: Surgical resection is the first-line treatment for hepatocellular carcinoma (HCC) patients with well-preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is as high as 70%, and this gravely jeopardizes the therapeutic outcome. Clearly, new approaches are needed for preventing the relapse of this deadly disease. Taking advantage of a luciferase-labeled orthotopic xenograft model of HCC, we examined the role of sorafenib, the first systemic drug approved for advanced HCC patients, in the prevention of HCC recurrence. We found that sorafenib suppressed the development of postsurgical intrahepatic recurrence and abdominal metastasis and consequently led to prolonged postoperative survival of mice in this model. Furthermore, hyperactivity of extracellular signal-regulated kinase signaling caused by elevated levels of growth factors associated with postoperative liver regeneration enhanced the sensitivity of HCC cells to sorafenib; this provides a plausible explanation for the observation that recurrent tumors are more responsive to growth inhibition by sorafenib. CONCLUSION: Our results strongly suggest that by effectively reducing postoperative recurrence, sorafenib has a potential application in early-stage HCC patients who have undergone hepatectomy with curative intention.

Duke Scholars

Published In

Hepatology

DOI

EISSN

1527-3350

Publication Date

February 2011

Volume

53

Issue

2

Start / End Page

483 / 492

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Heterologous
  • Sorafenib
  • Pyridines
  • Phenylurea Compounds
  • Niacinamide
  • Neoplasm Recurrence, Local
  • Neoplasm Metastasis
  • Mice, Nude
  • Mice, Inbred BALB C
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Feng, Y.-X., Wang, T., Deng, Y.-Z., Yang, P., Li, J.-J., Guan, D.-X., … Xie, D. (2011). Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology, 53(2), 483–492. https://doi.org/10.1002/hep.24075
Feng, Yu-Xiong, Tao Wang, Yue-Zhen Deng, Pengyuan Yang, Jing-Jing Li, Dong-Xian Guan, Fan Yao, et al. “Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.Hepatology 53, no. 2 (February 2011): 483–92. https://doi.org/10.1002/hep.24075.
Feng Y-X, Wang T, Deng Y-Z, Yang P, Li J-J, Guan D-X, et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology. 2011 Feb;53(2):483–92.
Feng, Yu-Xiong, et al. “Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.Hepatology, vol. 53, no. 2, Feb. 2011, pp. 483–92. Pubmed, doi:10.1002/hep.24075.
Feng Y-X, Wang T, Deng Y-Z, Yang P, Li J-J, Guan D-X, Yao F, Zhu Y-Q, Qin Y, Wang H, Li N, Wu M-C, Wang H-Y, Wang X-F, Cheng S-Q, Xie D. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology. 2011 Feb;53(2):483–492.
Journal cover image

Published In

Hepatology

DOI

EISSN

1527-3350

Publication Date

February 2011

Volume

53

Issue

2

Start / End Page

483 / 492

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Heterologous
  • Sorafenib
  • Pyridines
  • Phenylurea Compounds
  • Niacinamide
  • Neoplasm Recurrence, Local
  • Neoplasm Metastasis
  • Mice, Nude
  • Mice, Inbred BALB C